Gerri Henwood

President Donald Trump in March said he was considering suing drug companies fueling the opioid crisis — and Congress will allocate $6 billion in new funding over the next two years to advance the fight. The strategy, coupled with other policies, could bode well for Recro Pharma Inc (...

Recro Pharma Inc (NASDAQ: REPH) recently announced positive Phase 3 safety data for its palliative drug, IV Meloxicam, and CEO Gerri Henwood is eager to take the non-opioid, preferential COX-2 inhibitor to the next level. The company looks to file a New Drug Application with the Food and Drug...

Recro Pharma Inc (NASDAQ: REPH) is a clinical-stage pharmaceutical company that engages in the development of products for the treatment of serious acute pain. The company's lead product candidate is called meloxicam, which is an IV intravenous product for relief of serious pain that is...